Therefore, while inhibition of the Casp6 activation in AD brains can be considered as a potential therapy to prevent further pathophysiology, these results indicate that the therapeutic approach will need to carefully consider potential side effects on the gastrointestinal system. The gene discussed is CASP6; the disease is Alzheimer disease.